Takeda Pharmaceutical Company Limited announced today that it filed a NDA to the Ministry of Health, Labour and Welfare for a fixed-dose combination tablet of Actos® (pioglitazone HCI) with sulfonylurea for the treatment of type 2 diabetes.
The details can be read here.
No comments:
Post a Comment